Acidic tumour pH inhibits drug effect

February 11, 2014
Acidic tumour pH inhibits drug effect

Low pH in tumours counteracts the desired effect of the drug chloroquine, according to a new study from Karolinska Institutet in Sweden. The results, which are published in the journal Autophagy, might explain possible lack of efficacy of chloroquine in clinical studies.

Chloroquine, a widely used antimalaria drug, is currently under investigation in clinical trials on . It is the ability of to inhibit autophagy in that has piqued researchers' interest. Autophagy is a homeostatic process by which cells eat parts of themselves, so that damaged or unnecessary organelles and toxic proteins are broken down and recycled. In the absence of nutrients, cells resort to autophagy to survive. This way, autophagy helps survive in tumour regions that are poor in nutrients and characterised by low oxygen and acidic pH.

Also, tumour cells use autophagy to protect themselves from many forms of anticancer therapies, including chemotherapy. Several studies have shown that inhibition of autophagy often increases chemosensitivity and radiosensitivity in tumour cells. Chloroquine combined with existing cancer treatment is thus considered to be a promising strategy. However, in some cancer models chloroquine seems to be unable to block , but the underlying mechanisms have not yet been identified.

In the present study, the scientists studied the effect of chloroquine in different cancer cells that were either cultured in acidic pH for a short time or adapted to chronic acidosis. The researchers also studied the effect in tumours grown in mice.

"We discovered that a major consequence of the altered metabolism of tumour cells, the tissue acidification, is responsible for the lack of chloroquine anti-autophagic activity", says Angelo De Milito at the Department of Oncology-Pathology at Karolinska Institutet, principal investigator of the study. "The results suggest that chloroquine might lack efficacy in patients whose tumours are characterised by acidic regions."

In the context of cancer therapy, the finding may be of importance for the translation of preclinical findings to the clinical setting in patients. The research was funded by Association for International Cancer Research, the Swedish Cancer Society, and the Sigurd and Elsa Goljes Foundation.

Explore further: Autophagy-addicted breast cancers killed by anti-malaria drug, chloroquine

More information: Paola Pellegrini, Angela Strambi, Chiara Zipoli, Maria Hägg-Olofsson, Maria Buoncervello, Stig Linder, Angelo De Milito. "Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine; Implications for cancer therapies." Autophagy, online 31 January 2014, 10:4, 1-10, April 2014. www.ncbi.nlm.nih.gov/pubmed/24 … 72?dopt=AbstractPlus

Related Stories

Autophagy-addicted breast cancers killed by anti-malaria drug, chloroquine

April 8, 2013
The process of autophagy cleans cells – they wrap up the bad stuff and then dispose of it. And so it stands to reason that inhibiting autophagy would make cancer cells less able to cleanse themselves of chemotherapy and ...

Improved effectiveness of chemotherapy for cancer

August 15, 2013
Cancer cells often develop defence mechanisms which enable them to survive chemotherapy. A group of researchers from the Institutes of Pharmacology and Pathology in Bern present new solutions for preventing the development ...

Unusual combination therapy shows promise for preventing prostate cancer, researchers find

September 17, 2013
Combining a compound from broccoli with an antimalarial drug prevents prostate cancer in mice, University of Pittsburgh Cancer Institute (UPCI) researchers discovered.

Forcing cancer to digest itself

September 12, 2013
When tumour cells no longer degrade themselves, cancer may develop. Using black skin cancer as an example, Bern Researchers have now shown that a protein plays an important role in the process of degradation of tumour cells. ...

Autophagy predicts which cancer cells live and die when faced with anti-cancer drugs

January 10, 2014
(Medical Xpress)—When a tumor is treated with an anti-cancer drug, some cells die and, unfortunately, some cells tend to live. A University of Colorado Cancer Center study published in the journal Nature Cell Biology details ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.